Keith Biggadike
GlaxoSmithKline
84 Papers
1.1K Citations
Keith Biggadike is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Agonist & Alkyl. The author has an hindex of 22, co-authored 84 publications. Previous affiliations of Keith Biggadike include University of Oxford & University of Hertfordshire.
Chat about Author
Papers
Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease.
Mark Salter,Keith Biggadike,Joyce Lesley Matthews,Michael Robert West,Michael V. Haase,Stuart N. Farrow,Iain Uings,David W. Gray +7 more
TL;DR: The potent and selective pharmacological profile of FF described here could deliver an effective, safe, and sustained topical treatment of respiratory inflammatory diseases such as allergic rhinitis and asthma.
145
Patent
Phenylethanolamine derivatives for the treatment of respiratory diseases
Keith Biggadike,Keith GlaxoSmithKline Blake,Diane Mary Coe,Duncan S. Holmes,Panayiotis Alexandro Procopiou +4 more
- 30 Oct 2003
TL;DR: In this paper, the present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular the use in the prophylaxis and treatment of respiratory diseases.
106
Synthesis and Structure—Activity Relationships of Long-acting β2 Adrenergic Receptor Agonists Incorporating Metabolic Inactivation: An Antedrug Approach
Panayiotis A. Procopiou,Victoria J. Barrett,Nicola Bevan,Keith Biggadike,Philip Charles Box,Peter R. Butchers,Diane Mary Coe,Richard Conroy,Amanda Emmons,Alison J. Ford,Duncan S. Holmes,Helen Tracey Horsley,Fern Kerr,Anne-Marie Li-Kwai-Cheung,Brian Edgar Looker,Inderjit Singh Mann,Iain Mcfarlane Mclay,Valerie S. Morrison,Peter J. Mutch,Claire E. Smith,Paula Tomlin +20 more
TL;DR: Compound 13f had high potency, selectivity, fast onset, and long duration of action in vitro and was found to have long duration in vivo, low oral bioavailability in the rat, and to be rapidly metabolized.
102
Synthesis and enzymatic resolution of carbocyclic 2′-ara-fluoro-guanosine: a potent new anti-herpetic agent
Alan D. Borthwick,Suzanne Butt,Keith Biggadike,Anne M. Exall,Stanley M. Roberts,Peter Youds,Barrie E. Kirk,Brian R. Booth,Janet M. Cameron,Susan W. Cox,Clara L.P. Marr,Mark D. Shill +11 more
TL;DR: Carbocyclic-9-(2′-deoxy-2′ −β-fluoroarabinofuranosyl) guanine (8) and the corresponding furanose compound (12) have been synthesized; the former compound [which was resolved by formation of the monophosphate (20) and enantioselective hydrolysis using a 5′-nucleotidase] is an extremely potent inhibitor of herpes simplex viruses types 1 and 2.
74
Short convergent route to homochiral carbocyclic-2′-deoxynucleosides and carbocyclic ribonucleosides
Keith Biggadike,Alan D. Borthwick,Anne M. Exall,Barrie E. Kirk,Stanley M. Roberts,Peter Youds +5 more
TL;DR: The epoxide has been converted into the antiviral agents (5, 6, 7, and 8) and the epoxide furnished carbocyclic guanosine (12) as mentioned in this paper.
70